Compare Incyte Corporation (INCY) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Solaredge Technologies Inc — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while Solaredge Technologies Inc trades at $32.08 (market cap $2.00B). The key difference: Incyte Corporation is far larger — about 11.4× Solaredge Technologies Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Solaredge Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Solaredge Technologies Inc for 34 Days on average.
| INCY | SEDG | |
|---|---|---|
Market Cap | $22.85B | $2.00B |
Volume | 1,927,029 | 2,739,860 |
Sector | Health | Energy |
52-Week High | $129.93 | $78.51 |
52-Week Low | $83.80 | $28.47 |
Typical Hold Time | 33 Days | 34 Days |
Enterprise Value | $18.35B | $1.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
SolarEdge Technologies (SEDG) trades at $31.81, down 4.07% on the day, reflecting ongoing volatility amid a bearish technical signal and mixed earnings. The stock faces fundamental headwinds with a net loss of $405.45 million in 2025 and negative profit margins, though revenue grew to $1.18 billion. Recent news highlights legal investigations and AI data center initiatives, while analyst sentiment remains cautious with a $37.75 consensus target.
The outlook for SEDG is challenged by persistent losses and competitive pressures, but potential upside exists if AI-driven growth targets materialize. Key risks include execution on new initiatives, solar industry financing costs, and legal overhangs. Investors should weigh the high-risk profile against long-term transformation efforts under current market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
